In the third annual patient chart analysis, major treatment shifts in biologic use and average daily steroid dose were observed....
Adalimumab biosimilars hold potential to grow the overall biologic-treated population, but only if the cost savings translate to patients and...
Despite Vabysmo’s positive first impressions, the race is about to heat up with the widely anticipated FDA approval of Regeneron’s...
Ferring Pharmaceutical’s achieved an innovative milestone in C.Diff treatment when it launched Rebyota, the first FDA approved Fecal Microbiota Transplant...
New Spherix research highlights existing need for innovation in this underserved population EXTON, Pa., May 22, 2023 — The non-alcoholic...
Online platform underscores Spherix’s commitment to innovation by providing dynamic solutions generated from the company’s comprehensive insights library of reports...
Recent research suggests AbbVie has managed gastroenterologists’ concerns regarding JAK safety, setting up a potentially favorable encore in the Crohn’s...
U.S. specialists’ lack of satisfaction with current treatment options in cutaneous and discoid lupus paves the way for advanced pharmacological...
An FDA approval for Entyvio SC could exacerbate an already aggressive fight for second-line UC treatments. Exton, PA., May 4,...
Use of Trudhesa as an acute migraine treatment is on par with the more-established Reyvow, though future projections have it...
Concerns about ARIA and the associated monitoring requirements for Leqembi could present significant barriers to uptake. Exton, PA., April...
Spherix’s tracking data reveals use of Dupixent in EoE has tripled since its approval. Exton, PA., April 3, 2023 –...
